Price
No data yet.
Social Signal Score
Analyst Ratings
25 analystsRevenue
$364.25MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- William J. Sibold
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 915
- Beta
- -0.99
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 8.11
Financials
Revenue
$364.25M+2388.4%Net Income
$-57.94MEBITDA
$-56.31MFree Cash Flow
$19.08M+174.3%EPS (diluted)
$-1.99Shares Outstanding (diluted)
29.15M+229.4%Operating Expenses
$380.55MCash & Debt
$838.75MRevenue by Segment (annual)
$958.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $958.40M | $-288.28M | $-12.85 |
| 2024 | $180.13M | $-465.89M | $-21.90 |
| 2023 | $0.00 | $-373.63M | $-19.99 |
| 2022 | $0.00 | $-295.35M | $-17.23 |
| 2021 | $0.00 | $-241.85M | $-14.63 |
| 2020 | $0.00 | $-202.24M | $-13.09 |
| 2019 | $0.00 | $-83.95M | $-4.73 |
| 2018 | $0.00 | $-32.81M | $-2.22 |
| 2017 | $0.00 | $-31.15M | $-2.54 |
| 2016 | $0.00 | $-26.39M | $-5.07 |
| 2015 | $0.00 | $-6.84M | $-401.56 |
| 2014 | $0.00 | $-86.16M | $-30.62 |
| 2013 | $0.00 | $-90.19M | $-44.48 |
| 2012 | $0.00 | $-62.79M | $-36.99 |
Valuation
MDGLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
163+133.33%Social Signal Score
Mentions (6)
- News (RSS)seekingalpha·25d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)fool·25d ago·Neutral
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·52d ago·Neutral
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands Madrigal Pharmaceuticals NASDAQ: MDGL said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Madrigal Appoints John C. Reed, M.D. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.84 per share
Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-1.99 vs $-2.68beat
- Wed, May 6$-3.25 vs $-3.61beat
- Thu, Feb 19$-2.57 vs $0.04miss
- Tue, Nov 4$-5.08 vs $-2.04miss
- Tue, Aug 5$-1.90 vs $-3.48beat
- Thu, May 1$-3.32 vs $-3.62beat
Estimates and results for MDGL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDGL officers and directors.
- Bought
- —
- Sold
- $14.9m
0 trades
68 trades
- Sibold William Johnsold
- Sibold William Johnsold
- Sibold William Johnsold
- Sibold William Johnsold
- Sibold William Johnsold
- Sibold William Johnsold
- Sibold William Johnsold
- Sibold William Johnsold
32 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.